RF1AG075904
Project Grant
Overview
Grant Description
Alzheimer's Disease and Related Dementias (ADRD) Prevalence in American Samoa - Abstract
Alzheimer’s disease and related dementias (ADRD) affects over 5.7 million Americans and over 35 million people worldwide. Indigenous populations, including American Indians, Alaskan Natives, Native Hawaiians, and Pacific Islanders, are increasingly concerned about ADRD and its prodromal state, mild cognitive impairment (MCI), as these conditions exert a major impact on their communities. Although these populations are culturally diverse and geographically dispersed, they share a high prevalence of well-established ADRD risk factors.
Life expectancies in indigenous populations have increased over the past five decades, resulting in a three-fold increase in people over the age of 65. These changing demographics have made ADRD potentially more visible to communities. However, the healthcare systems that serve these populations are unprepared for the patient, caregiver, social, and economic burdens associated with ADRD. Unfortunately, these same communities have low health literacy and limited research readiness needed to address the growing problem of ADRD.
Situated in the heart of the South Pacific, American Samoa is the only U.S. territory located south of the equator. The 2020 U.S. Census recorded 49,710 residents, with 11,025 (4.1%) of the population over the age of 50. Currently, there are no known studies that document ADRD prevalence within the Samoan population.
Our overarching objective is to build upon our prior work, test novel approaches to increase ADRD literacy and research readiness, improve detection of ADRD, and build upon a nascent research infrastructure to conduct important phenotypic and genotypic characterization of ADRD in American Samoa. Our specific aims are:
1. Test ADRD knowledge, health literacy, research readiness, and determine ADRD resilience and vulnerability factors, and cognitive status in a probability sample of 981 Samoans age 50+ using culturally adapted instruments in our probability sample.
2. Conduct gold standard evaluations in our probability sample using the Uniform Data Set (UDSV3.0) from the NIA Alzheimer’s Disease Research Center Program to determine a population-based prevalence of MCI and ADRD for harmonization, data sharing, and comparison to other groups.
3. Cross-validate gold standard dementia evaluations with genetic (i.e., APOE) and plasma amyloid-tau-neuronal injury/neurodegeneration (ATN) framework (e.g., A 40, A42, P-TAU, NFL, GFAP) biomarkers in our probability sample and compare to information available for other racial/ethnic groups.
The dearth of relevant clinical and programmatic knowledge hampers efforts by clinicians, scientists, policymakers, and communities to reduce ADRD disparities in American Samoa. Our short-term goal is to determine ADRD prevalence and study resilience and vulnerability factors contributing to ADRD in American Samoa and share resources with other investigators. Our long-term goal is to foster future research efforts to increase accurate and early diagnosis, expand access to care, and improve health outcomes in American Samoa.
Alzheimer’s disease and related dementias (ADRD) affects over 5.7 million Americans and over 35 million people worldwide. Indigenous populations, including American Indians, Alaskan Natives, Native Hawaiians, and Pacific Islanders, are increasingly concerned about ADRD and its prodromal state, mild cognitive impairment (MCI), as these conditions exert a major impact on their communities. Although these populations are culturally diverse and geographically dispersed, they share a high prevalence of well-established ADRD risk factors.
Life expectancies in indigenous populations have increased over the past five decades, resulting in a three-fold increase in people over the age of 65. These changing demographics have made ADRD potentially more visible to communities. However, the healthcare systems that serve these populations are unprepared for the patient, caregiver, social, and economic burdens associated with ADRD. Unfortunately, these same communities have low health literacy and limited research readiness needed to address the growing problem of ADRD.
Situated in the heart of the South Pacific, American Samoa is the only U.S. territory located south of the equator. The 2020 U.S. Census recorded 49,710 residents, with 11,025 (4.1%) of the population over the age of 50. Currently, there are no known studies that document ADRD prevalence within the Samoan population.
Our overarching objective is to build upon our prior work, test novel approaches to increase ADRD literacy and research readiness, improve detection of ADRD, and build upon a nascent research infrastructure to conduct important phenotypic and genotypic characterization of ADRD in American Samoa. Our specific aims are:
1. Test ADRD knowledge, health literacy, research readiness, and determine ADRD resilience and vulnerability factors, and cognitive status in a probability sample of 981 Samoans age 50+ using culturally adapted instruments in our probability sample.
2. Conduct gold standard evaluations in our probability sample using the Uniform Data Set (UDSV3.0) from the NIA Alzheimer’s Disease Research Center Program to determine a population-based prevalence of MCI and ADRD for harmonization, data sharing, and comparison to other groups.
3. Cross-validate gold standard dementia evaluations with genetic (i.e., APOE) and plasma amyloid-tau-neuronal injury/neurodegeneration (ATN) framework (e.g., A 40, A42, P-TAU, NFL, GFAP) biomarkers in our probability sample and compare to information available for other racial/ethnic groups.
The dearth of relevant clinical and programmatic knowledge hampers efforts by clinicians, scientists, policymakers, and communities to reduce ADRD disparities in American Samoa. Our short-term goal is to determine ADRD prevalence and study resilience and vulnerability factors contributing to ADRD in American Samoa and share resources with other investigators. Our long-term goal is to foster future research efforts to increase accurate and early diagnosis, expand access to care, and improve health outcomes in American Samoa.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
American Samoa
United States
Geographic Scope
State-Wide
American Samoa Community Cancer Coalition was awarded
ADRD Prevalence in American Samoa
Project Grant RF1AG075904
worth $6,186,533
from National Institute on Aging in September 2022 with work to be completed primarily in American Samoa United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/20/23
Period of Performance
9/30/22
Start Date
8/31/25
End Date
Funding Split
$6.2M
Federal Obligation
$0.0
Non-Federal Obligation
$6.2M
Total Obligated
Activity Timeline
Transaction History
Modifications to RF1AG075904
Additional Detail
Award ID FAIN
RF1AG075904
SAI Number
RF1AG075904-963256756
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NN00 NIH NATIONAL INSITUTE ON AGING
Funding Office
75NN00 NIH NATIONAL INSITUTE ON AGING
Awardee UEI
FJDGHK4JKNR1
Awardee CAGE
4TCG9
Performance District
AS-98
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) | Health research and training | Grants, subsidies, and contributions (41.0) | $6,186,533 | 100% |
Modified: 9/20/23